ZNTL
vs
S&P 500
ZNTL
S&P 500
Over the past 12 months, ZNTL has underperformed S&P 500, delivering a return of -55% compared to the S&P 500's +12% growth.
Stocks Performance
ZNTL vs S&P 500
Performance Gap
ZNTL vs S&P 500
Performance By Year
ZNTL vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Zentalis Pharmaceuticals Inc
Glance View
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 177 full-time employees. The company went IPO on 2020-04-03. The company is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
